Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase

NCT03531320 is registered in ClinicalTrials.gov with InnoPharmax Inc. as lead sponsor.

NCT NCT03531320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03531320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase
Lead sponsor
InnoPharmax Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 6, 2018
Completion date
December 29, 2020
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, gastrointestinal cancer